TX-MARY-KAY-INC
3.4.2024 20:13:34 CEST | Business Wire | Press release
Mary Kay Inc., a global leader in women’s empowerment and staunch advocate for sustainability, is once again at the forefront of global ocean conservation efforts. The beauty brand was proud to participate at the 11th Annual World Ocean Summit & Expo, held in Lisbon, Portugal, from March 11-13. As a bronze level sponsor for the second consecutive year, Mary Kay demonstrated its unwavering commitment to fostering a sustainable blue economy as a private sector representative and through its long-standing collaboration with The Nature Conservancy (TNC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403166440/en/
Sandra Silva, General Manager of Mary Kay in Portugal, shared insights on the crucial need for collaborative efforts in marine conservation and highlighted the impact of incorporating gender perspectives in initiatives tackling climate change challenges and biodiversity loss. (Photo: Mary Kay Inc.)
The Annual World Ocean Summit & Expo, organized by Economist Impact, convened over 200 expert speakers and a diverse international audience to engage in meaningful discussions, workshops, and "How to" sessions. These gatherings focused on actionable solutions to some of the most pressing oceanic challenges, underlining the importance of collaborative efforts across sectors.
Sandra Silva, General Manager of Mary Kay Portugal, took an active role in the panel discussion titled "Developing Blue Nature-based Projects." Silva shared insights on the crucial need for collaborative efforts in marine conservation and highlighted the impact of incorporating gender perspectives in initiatives tackling climate change challenges and biodiversity loss.
"Mary Kay's participation at this year's World Ocean Summit was not only about reinforcing our dedication to ocean conservation, but also about spotlighting the essential role of women in these efforts,” said Silva. “We believe that our collective actions today are pivotal for the preservation of marine ecosystems. All stakeholders left the summit with a clear vision on new synergies, a focus on actionable strategies, and soundproof solutions to enhance ocean stewardship.”
Dr. Lizzie Mcleod, Global Ocean Director for The Nature Conservancy, expressed gratitude for their long-term and impactful relationship with Mary Kay. "Our strong collaboration stands as a testament to the power of joining forces across the scientific community and the private sector to improve ocean health. Mary Kay’s support of marine conservation initiatives, including the Super Reefs project in Palau, is one example of our collective effort to ensure a healthy and resilient ocean."
Mary Kay has been working to elevate ocean health and coral reef awareness through its support of The Nature Conservancy for 37 years. Some of the most recent projects include the Super Reef restoration in the Asia Pacific region and other projects in Hawaii, Palau, the Marshall Islands, and Belize. These projects align with Mary Kay's mission to not only enrich lives but also to ensure the longevity and health of marine environments for future generations.
DID YOU KNOW?
- Mary Kay began supporting The Nature Conservancy (TNC) in 1987 and has now contributed to projects for more than three decades across 100 conservation projects around the globe.
- As part of its mission to conserve the Earth’s land and water, TNC aims to conserve 4 billion hectares of ocean by 2030—including coral reefs.
- Out of more than 1,500 articles published on coral reef sciences in OECD countries, 33% of authors were women.1
- 13-24% of senior positions in the EU’s marine sciences sector are occupied by women.1
- 90% of women in fisheries and aquaculture are more involved in less well-paid or unpaid work.1
About Mary Kay
Then. Now. Always. One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 35 countries. For 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on X (formerly Twitter).
About The Nature Conservancy
The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our world’s toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters, and oceans at an unprecedented scale, providing food and water sustainably, and helping make cities more sustainable. Working in 76 countries and territories —37 by direct conservation impact and 39 through partners— we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit www.nature.org or follow @nature_press on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403166440/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
